CCL2 and prostate carcinoma: This study used a mouse model of prostate cancer in the bone treated with combinations of docetaxel and CCL2 neutralizing antibodies, and reported that CCL2 neutralization inhibited metastatic prostate cancer lesions to the bone, an effect that is enhanced by combination with the first line taxane chemotherapy, docetaxel [145].